Effect of Dapagliflozin on Clinical Outcomes in Patients With Chronic Kidney Disease, With and Without Cardiovascular Disease | Zendy

John J.V. McMurray | Zendy; David C. Wheeler | Zendy; Bergur V. Stefánsson | Zendy; Niels Jongs | Zendy; Douwe Postmus | Zendy; Ricardo CorreaRotter | Zendy; Glenn M. Chertow | Zendy; Tom Greene | Zendy; Claes Held | Zendy; Fan Fan Hou | Zendy; Johannes F.E. Mann | Zendy; Peter Rossing | Zendy; C. David Sjöström | Zendy; Roberto D. Toto | Zendy; Anna Maria Langkilde | Zendy; Hiddo J.L. Heerspink | Zendy

Open Access

Effect of Dapagliflozin on Clinical Outcomes in Patients With Chronic Kidney Disease, With and Without Cardiovascular Disease

Author(s) -

John J.V. McMurray,

David C. Wheeler,

Bergur V. Stefánsson,

Niels Jongs,

Douwe Postmus,

Ricardo CorreaRotter,

Glenn M. Chertow,

Tom Greene,

Claes Held,

Fan Fan Hou,

Johannes F.E. Mann,

Peter Rossing,

C. David Sjöström,

Roberto D. Toto,

Anna Maria Langkilde,

Hiddo J.L. Heerspink

Publication year - 2020

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.120.051675

Subject(s) - medicine , dapagliflozin , kidney disease , disease , intensive care medicine , cardiology , diabetes mellitus , endocrinology , type 2 diabetes

Dapagliflozin reduces the risk of end-stage renal disease in patients with chronic kidney disease. We examined the relative risk of cardiovascular and renal events in these patients and the effect of dapagliflozin on either type of event, taking account of history of cardiovascular disease.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research